z-logo
open-access-imgOpen Access
Opportunities for Synthetic Biology in Antibiotics: Expanding Glycopeptide Chemical Diversity
Author(s) -
Maulik Thaker,
Gerard D. Wright
Publication year - 2012
Publication title -
acs synthetic biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.156
H-Index - 66
ISSN - 2161-5063
DOI - 10.1021/sb300092n
Subject(s) - glycopeptide , synthetic biology , antibiotic resistance , antibiotics , biology , diversity (politics) , chemical biology , computational biology , microbiology and biotechnology , drug discovery , drug development , drug resistance , antimicrobial , drug , bioinformatics , genetics , political science , pharmacology , law
Synthetic biology offers a new path for the exploitation and improvement of natural products to address the growing crisis in antibiotic resistance. All antibiotics in clinical use are facing eventual obsolesce as a result of the evolution and dissemination of resistance mechanisms, yet there are few new drug leads forthcoming from the pharmaceutical sector. Natural products of microbial origin have proven over the past 70 years to be the wellspring of antimicrobial drugs. Harnessing synthetic biology thinking and strategies can provide new molecules and expand chemical diversity of known antibiotic scaffolds to provide much needed new drug leads. The glycopeptide antibiotics offer paradigmatic scaffolds suitable for such an approach. We review these strategies here using the glycopeptides as an example and demonstrate how synthetic biology can expand antibiotic chemical diversity to help address the growing resistance crisis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom